COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4103-4113

  Scheper, Mark A ^a   Sauk, John J ^b   Nikitakis, Nikolaus G ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

COX; Head and neck cancer; Squamous cell carcinoma; Sulindac; Survivin

Indexed keywords

CELECOXIB; COMPLEMENTARY DNA; CYCLOOXYGENASE 1 INHIBITOR; INDOMETACIN; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; SMALL INTERFERING RNA; SULINDAC; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DNA PRIMERS; DOWN-REGULATION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, SMALL INTERFERING; SULINDAC;

EID: 33845962246     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Li F: Survivin study: what is the next wave? J Cell Physiol 197: 8-29, 2003.
3. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
4. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M and Altieri DC: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62: 2462-2467, 2002.
5. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA, Procaccini M, Ferrari F, De Rosa G and Altieri DC: Survivin expression in oral squamous cell carcinoma. Br J Cancer 89: 2244-2248, 2003.
6. Chiou SK, Jones MK and Tarnawski AJ: Survivin- an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9: 43-47, 2003.
7. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC and Altieri DC: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J of Cell Sci 115: 575-585, 2002.
8. Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J, Murphy LM, Chen L, Wettstein PJ, Gostout B, Ferrone S and Strome SE: Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer 97: 2203-2211, 2003.
9. Dong Y, Sui L, Watanabe Y, Sugimoto K and Tokuda M: Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 22: 2377-2384, 2002.
10. Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T and Altieri DC: Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dental Res 82: 923-928, 2003.
11. Zhang T, Fields JZ, Ehrlich SM and Boman BM: The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308: 434-437, 2004.
12. Teh SH, Hill AK, Foley DA, McDermott EW, O'Higgins NJ and Young LS: COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J Cell Biochem 91: 796-807, 2004.
13. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S and Dubinett S: COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18: 206-208, 2004.
14. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Transcriptional analysis of human survivin gene expression. Nature 396: 580-584, 1998.
15. Nikitakis NG, Hebert C, Lopes MA, Reynolds MA and Sauk JJ: PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer 98: 817-823, 2002.
16. Shiff SJ, Qiao L, Tsai LL and Rigas B: Sulindac sulfide, an asprin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
17. Piazza GA, Raham AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS and Pamukcu R: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116, 1995.
18. Elder DJ, Halton DE, Hague A and Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3: 1679-1683, 1997.
19. Claria J and Romano M: Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 11: 3431-3447, 2005.
20. Choe MS, Zhang X, Shin HJ, Shin DM and Chen ZG: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4: 1448-1455, 2005.
21. Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270: G393-400, 1996.
22. Rigas B, Goldman IS and Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523, 1993.
23. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL and Dannenberg AJ: Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999.
24. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
25. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
26. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2- dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998.
27. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
28. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
29. Mohan S and Epstein JB: Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 39: 537-546, 2003.
30. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ and Boyle JO: Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24: 792-799, 2002.
31. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003.
32. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI and Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin- independent pathway. Biochem Pharmacol 52: 237-245, 1996.
33. de Mello MC, Bayer BM and Beaven MA: Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem Pharmacol 29: 311-318, 1980.
34. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
35. Yang CY, Meng CL, Liao CL and Wong PY: Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins Other Lipid Mediat 72: 115-130, 2003.
36. Akita Y, Kozaki K, Nakagawa A, Saito T, Ito S, Tamada Y, Fujiwara S, Nishikawa N, Uchida K, Yoshikawa K, Noguchi T, Miyaishi O, Shimozato K, Saga S and Matsumoto Y: Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br J Dermatol 151: 472-480, 2004.
37. Ye F, Wu J, Dunn T, Yi J, Tong X and Zhang D: Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett 211: 39-46, 2004.
38. Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D and Nagumo M: Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 21: 737-745, 2004.
39. Ding H, Han C, Zhu J, Chen CS and D'Ambrosio SM: Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113: 803-810, 2005.
40. Yang CC, Tu SF, Wu CH, Chang RC and Kao SY: In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis. Zhonghua Yi Xue Za Zhi 65: 600-607, 2002.
41. Thurnher D, Bakroeva M, Schutz G, Pelzmann M, Formanek M, Knerer B and Kornfehl J: Non-steroidal anti-inflammatory drugs induce apoptosis in head and neck cancer cell lines. Acta Otolaryngol 121: 957-962, 2001.
42. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307-27314, 1999.
43. Kobayashi M, Nakamura S, Shibata K, Sahara N, Shigeno K, Shinjo K, Naito K and Ohnishi K: Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol 75: 212-220, 2005.
44. Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Mariggio A, Salvatore G, Chieffi P, Tramontano D, De Rosa G and Altieri DC: Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol 70: 249-254, 2001.
45. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H and Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J of Dent Res 82: 607-611, 2003.
46. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A and Kawada M: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004.
47. Aoki Y, Feldman GM and Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535-1542, 2003.
48. Nikitakis NG, Hamburger AW and Sauk JJ: The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res 62: 1004-1007, 2002.
49. Kohli M, Yu J, Seaman C, Bardelli A, Kinzler KW, Vogelstein B, Lengauer C and Zhang L: SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci USA 101: 16897-16902, 2004.
50. Reed JC: The survivin saga goes in vivo. J Clin Invest 108: 965-969, 2001.